nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—osteoarthritis—Prednisone—ankylosing spondylitis	0.256	0.5	CpDpCtD
Meloxicam—osteoarthritis—Methylprednisolone—ankylosing spondylitis	0.256	0.5	CpDpCtD
Meloxicam—PGD—Methotrexate—ankylosing spondylitis	0.117	0.28	CbGbCtD
Meloxicam—PTGS2—Sulfasalazine—ankylosing spondylitis	0.0473	0.113	CbGbCtD
Meloxicam—PTGS2—Triamcinolone—ankylosing spondylitis	0.0473	0.113	CbGbCtD
Meloxicam—PTGS2—Betamethasone—ankylosing spondylitis	0.0406	0.0973	CbGbCtD
Meloxicam—PTGS1—Sulfasalazine—ankylosing spondylitis	0.04	0.0957	CbGbCtD
Meloxicam—ABCC4—Methotrexate—ankylosing spondylitis	0.0323	0.0774	CbGbCtD
Meloxicam—PTGS2—Dexamethasone—ankylosing spondylitis	0.0236	0.0566	CbGbCtD
Meloxicam—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0123	0.0296	CbGbCtD
Meloxicam—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0115	0.0276	CbGbCtD
Meloxicam—CYP3A4—Triamcinolone—ankylosing spondylitis	0.00936	0.0224	CbGbCtD
Meloxicam—CYP2C9—Dexamethasone—ankylosing spondylitis	0.00803	0.0192	CbGbCtD
Meloxicam—CYP3A4—Betamethasone—ankylosing spondylitis	0.00803	0.0192	CbGbCtD
Meloxicam—CYP3A4—Prednisolone—ankylosing spondylitis	0.00792	0.019	CbGbCtD
Meloxicam—CYP3A4—Prednisone—ankylosing spondylitis	0.00748	0.0179	CbGbCtD
Meloxicam—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00467	0.0112	CbGbCtD
Meloxicam—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.000437	0.159	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.00043	0.156	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.00043	0.156	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000421	0.153	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.000264	0.0957	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	0.00026	0.0942	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	0.00026	0.0942	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	0.000254	0.0921	CbGdCrCtD
Meloxicam—Infection—Methylprednisolone—ankylosing spondylitis	0.000101	0.0015	CcSEcCtD
Meloxicam—Haematuria—Methotrexate—ankylosing spondylitis	0.000101	0.0015	CcSEcCtD
Meloxicam—Shock—Triamcinolone—ankylosing spondylitis	0.0001	0.00149	CcSEcCtD
Meloxicam—Insomnia—Prednisolone—ankylosing spondylitis	0.0001	0.00149	CcSEcCtD
Meloxicam—Alopecia—Prednisone—ankylosing spondylitis	0.0001	0.00149	CcSEcCtD
Meloxicam—Shock—Methylprednisolone—ankylosing spondylitis	0.0001	0.00149	CcSEcCtD
Meloxicam—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	9.99e-05	0.00148	CcSEcCtD
Meloxicam—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	9.98e-05	0.00148	CcSEcCtD
Meloxicam—Loss of consciousness—Dexamethasone—ankylosing spondylitis	9.97e-05	0.00148	CcSEcCtD
Meloxicam—Loss of consciousness—Betamethasone—ankylosing spondylitis	9.97e-05	0.00148	CcSEcCtD
Meloxicam—Paraesthesia—Prednisolone—ankylosing spondylitis	9.96e-05	0.00148	CcSEcCtD
Meloxicam—Tachycardia—Triamcinolone—ankylosing spondylitis	9.96e-05	0.00148	CcSEcCtD
Meloxicam—Mental disorder—Prednisone—ankylosing spondylitis	9.94e-05	0.00148	CcSEcCtD
Meloxicam—Tachycardia—Methylprednisolone—ankylosing spondylitis	9.93e-05	0.00148	CcSEcCtD
Meloxicam—Skin disorder—Methylprednisolone—ankylosing spondylitis	9.89e-05	0.00147	CcSEcCtD
Meloxicam—Malnutrition—Prednisone—ankylosing spondylitis	9.88e-05	0.00147	CcSEcCtD
Meloxicam—Erythema—Prednisone—ankylosing spondylitis	9.88e-05	0.00147	CcSEcCtD
Meloxicam—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	9.86e-05	0.00146	CcSEcCtD
Meloxicam—Agranulocytosis—Methotrexate—ankylosing spondylitis	9.86e-05	0.00146	CcSEcCtD
Meloxicam—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	9.84e-05	0.00146	CcSEcCtD
Meloxicam—Convulsion—Dexamethasone—ankylosing spondylitis	9.83e-05	0.00146	CcSEcCtD
Meloxicam—Convulsion—Betamethasone—ankylosing spondylitis	9.83e-05	0.00146	CcSEcCtD
Meloxicam—Hypertension—Betamethasone—ankylosing spondylitis	9.79e-05	0.00145	CcSEcCtD
Meloxicam—Hypertension—Dexamethasone—ankylosing spondylitis	9.79e-05	0.00145	CcSEcCtD
Meloxicam—Myalgia—Betamethasone—ankylosing spondylitis	9.65e-05	0.00143	CcSEcCtD
Meloxicam—Myalgia—Dexamethasone—ankylosing spondylitis	9.65e-05	0.00143	CcSEcCtD
Meloxicam—Anxiety—Betamethasone—ankylosing spondylitis	9.62e-05	0.00143	CcSEcCtD
Meloxicam—Anxiety—Dexamethasone—ankylosing spondylitis	9.62e-05	0.00143	CcSEcCtD
Meloxicam—Discomfort—Betamethasone—ankylosing spondylitis	9.54e-05	0.00142	CcSEcCtD
Meloxicam—Discomfort—Dexamethasone—ankylosing spondylitis	9.54e-05	0.00142	CcSEcCtD
Meloxicam—Haemoglobin—Methotrexate—ankylosing spondylitis	9.53e-05	0.00142	CcSEcCtD
Meloxicam—Hypotension—Methylprednisolone—ankylosing spondylitis	9.51e-05	0.00141	CcSEcCtD
Meloxicam—Pain—Prednisolone—ankylosing spondylitis	9.49e-05	0.00141	CcSEcCtD
Meloxicam—Haemorrhage—Methotrexate—ankylosing spondylitis	9.48e-05	0.00141	CcSEcCtD
Meloxicam—Hepatitis—Methotrexate—ankylosing spondylitis	9.48e-05	0.00141	CcSEcCtD
Meloxicam—Pharyngitis—Methotrexate—ankylosing spondylitis	9.41e-05	0.0014	CcSEcCtD
Meloxicam—Urinary tract disorder—Methotrexate—ankylosing spondylitis	9.36e-05	0.00139	CcSEcCtD
Meloxicam—Vision blurred—Prednisone—ankylosing spondylitis	9.31e-05	0.00138	CcSEcCtD
Meloxicam—Urethral disorder—Methotrexate—ankylosing spondylitis	9.29e-05	0.00138	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	9.29e-05	0.00138	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	9.27e-05	0.00138	CcSEcCtD
Meloxicam—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	9.26e-05	0.00137	CcSEcCtD
Meloxicam—Oedema—Betamethasone—ankylosing spondylitis	9.26e-05	0.00137	CcSEcCtD
Meloxicam—Anaphylactic shock—Betamethasone—ankylosing spondylitis	9.26e-05	0.00137	CcSEcCtD
Meloxicam—Oedema—Dexamethasone—ankylosing spondylitis	9.26e-05	0.00137	CcSEcCtD
Meloxicam—Insomnia—Triamcinolone—ankylosing spondylitis	9.23e-05	0.00137	CcSEcCtD
Meloxicam—Insomnia—Methylprednisolone—ankylosing spondylitis	9.21e-05	0.00137	CcSEcCtD
Meloxicam—Infection—Dexamethasone—ankylosing spondylitis	9.19e-05	0.00137	CcSEcCtD
Meloxicam—Infection—Betamethasone—ankylosing spondylitis	9.19e-05	0.00137	CcSEcCtD
Meloxicam—Ill-defined disorder—Prednisone—ankylosing spondylitis	9.16e-05	0.00136	CcSEcCtD
Meloxicam—Paraesthesia—Triamcinolone—ankylosing spondylitis	9.16e-05	0.00136	CcSEcCtD
Meloxicam—Feeling abnormal—Prednisolone—ankylosing spondylitis	9.14e-05	0.00136	CcSEcCtD
Meloxicam—Paraesthesia—Methylprednisolone—ankylosing spondylitis	9.14e-05	0.00136	CcSEcCtD
Meloxicam—Visual impairment—Methotrexate—ankylosing spondylitis	9.14e-05	0.00136	CcSEcCtD
Meloxicam—Anaemia—Prednisone—ankylosing spondylitis	9.13e-05	0.00136	CcSEcCtD
Meloxicam—Shock—Dexamethasone—ankylosing spondylitis	9.11e-05	0.00135	CcSEcCtD
Meloxicam—Shock—Betamethasone—ankylosing spondylitis	9.11e-05	0.00135	CcSEcCtD
Meloxicam—Dyspnoea—Triamcinolone—ankylosing spondylitis	9.09e-05	0.00135	CcSEcCtD
Meloxicam—Nervous system disorder—Betamethasone—ankylosing spondylitis	9.08e-05	0.00135	CcSEcCtD
Meloxicam—Nervous system disorder—Dexamethasone—ankylosing spondylitis	9.08e-05	0.00135	CcSEcCtD
Meloxicam—Thrombocytopenia—Betamethasone—ankylosing spondylitis	9.06e-05	0.00135	CcSEcCtD
Meloxicam—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	9.06e-05	0.00135	CcSEcCtD
Meloxicam—Tachycardia—Dexamethasone—ankylosing spondylitis	9.03e-05	0.00134	CcSEcCtD
Meloxicam—Tachycardia—Betamethasone—ankylosing spondylitis	9.03e-05	0.00134	CcSEcCtD
Meloxicam—Angioedema—Prednisone—ankylosing spondylitis	9.02e-05	0.00134	CcSEcCtD
Meloxicam—Dyspepsia—Triamcinolone—ankylosing spondylitis	8.98e-05	0.00133	CcSEcCtD
Meloxicam—Erythema multiforme—Methotrexate—ankylosing spondylitis	8.96e-05	0.00133	CcSEcCtD
Meloxicam—Dyspepsia—Methylprednisolone—ankylosing spondylitis	8.96e-05	0.00133	CcSEcCtD
Meloxicam—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	8.95e-05	0.00133	CcSEcCtD
Meloxicam—Hyperhidrosis—Betamethasone—ankylosing spondylitis	8.95e-05	0.00133	CcSEcCtD
Meloxicam—Malaise—Prednisone—ankylosing spondylitis	8.91e-05	0.00132	CcSEcCtD
Meloxicam—Vertigo—Prednisone—ankylosing spondylitis	8.87e-05	0.00132	CcSEcCtD
Meloxicam—Eye disorder—Methotrexate—ankylosing spondylitis	8.86e-05	0.00132	CcSEcCtD
Meloxicam—Syncope—Prednisone—ankylosing spondylitis	8.86e-05	0.00132	CcSEcCtD
Meloxicam—Tinnitus—Methotrexate—ankylosing spondylitis	8.84e-05	0.00131	CcSEcCtD
Meloxicam—Urticaria—Prednisolone—ankylosing spondylitis	8.81e-05	0.00131	CcSEcCtD
Meloxicam—Cardiac disorder—Methotrexate—ankylosing spondylitis	8.8e-05	0.00131	CcSEcCtD
Meloxicam—Fatigue—Triamcinolone—ankylosing spondylitis	8.79e-05	0.00131	CcSEcCtD
Meloxicam—Fatigue—Methylprednisolone—ankylosing spondylitis	8.77e-05	0.0013	CcSEcCtD
Meloxicam—Pain—Triamcinolone—ankylosing spondylitis	8.72e-05	0.0013	CcSEcCtD
Meloxicam—Loss of consciousness—Prednisone—ankylosing spondylitis	8.68e-05	0.00129	CcSEcCtD
Meloxicam—Hypotension—Dexamethasone—ankylosing spondylitis	8.65e-05	0.00128	CcSEcCtD
Meloxicam—Hypotension—Betamethasone—ankylosing spondylitis	8.65e-05	0.00128	CcSEcCtD
Meloxicam—Angiopathy—Methotrexate—ankylosing spondylitis	8.6e-05	0.00128	CcSEcCtD
Meloxicam—Immune system disorder—Methotrexate—ankylosing spondylitis	8.56e-05	0.00127	CcSEcCtD
Meloxicam—Convulsion—Prednisone—ankylosing spondylitis	8.56e-05	0.00127	CcSEcCtD
Meloxicam—Mediastinal disorder—Methotrexate—ankylosing spondylitis	8.54e-05	0.00127	CcSEcCtD
Meloxicam—Hypertension—Prednisone—ankylosing spondylitis	8.53e-05	0.00127	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	8.43e-05	0.00125	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	8.43e-05	0.00125	CcSEcCtD
Meloxicam—Myalgia—Prednisone—ankylosing spondylitis	8.41e-05	0.00125	CcSEcCtD
Meloxicam—Arthralgia—Prednisone—ankylosing spondylitis	8.41e-05	0.00125	CcSEcCtD
Meloxicam—Feeling abnormal—Triamcinolone—ankylosing spondylitis	8.41e-05	0.00125	CcSEcCtD
Meloxicam—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	8.39e-05	0.00125	CcSEcCtD
Meloxicam—Anxiety—Prednisone—ankylosing spondylitis	8.38e-05	0.00124	CcSEcCtD
Meloxicam—Alopecia—Methotrexate—ankylosing spondylitis	8.38e-05	0.00124	CcSEcCtD
Meloxicam—Insomnia—Dexamethasone—ankylosing spondylitis	8.37e-05	0.00124	CcSEcCtD
Meloxicam—Insomnia—Betamethasone—ankylosing spondylitis	8.37e-05	0.00124	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	8.35e-05	0.00124	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	8.32e-05	0.00124	CcSEcCtD
Meloxicam—Paraesthesia—Betamethasone—ankylosing spondylitis	8.31e-05	0.00123	CcSEcCtD
Meloxicam—Paraesthesia—Dexamethasone—ankylosing spondylitis	8.31e-05	0.00123	CcSEcCtD
Meloxicam—Discomfort—Prednisone—ankylosing spondylitis	8.31e-05	0.00123	CcSEcCtD
Meloxicam—Mental disorder—Methotrexate—ankylosing spondylitis	8.31e-05	0.00123	CcSEcCtD
Meloxicam—Erythema—Methotrexate—ankylosing spondylitis	8.25e-05	0.00123	CcSEcCtD
Meloxicam—Malnutrition—Methotrexate—ankylosing spondylitis	8.25e-05	0.00123	CcSEcCtD
Meloxicam—Hypersensitivity—Prednisolone—ankylosing spondylitis	8.17e-05	0.00121	CcSEcCtD
Meloxicam—Dyspepsia—Betamethasone—ankylosing spondylitis	8.15e-05	0.00121	CcSEcCtD
Meloxicam—Dyspepsia—Dexamethasone—ankylosing spondylitis	8.15e-05	0.00121	CcSEcCtD
Meloxicam—Urticaria—Triamcinolone—ankylosing spondylitis	8.1e-05	0.0012	CcSEcCtD
Meloxicam—Urticaria—Methylprednisolone—ankylosing spondylitis	8.09e-05	0.0012	CcSEcCtD
Meloxicam—Dysgeusia—Methotrexate—ankylosing spondylitis	8.08e-05	0.0012	CcSEcCtD
Meloxicam—Body temperature increased—Triamcinolone—ankylosing spondylitis	8.06e-05	0.0012	CcSEcCtD
Meloxicam—Oedema—Prednisone—ankylosing spondylitis	8.06e-05	0.0012	CcSEcCtD
Meloxicam—Anaphylactic shock—Prednisone—ankylosing spondylitis	8.06e-05	0.0012	CcSEcCtD
Meloxicam—Abdominal pain—Methylprednisolone—ankylosing spondylitis	8.05e-05	0.00119	CcSEcCtD
Meloxicam—Decreased appetite—Betamethasone—ankylosing spondylitis	8.05e-05	0.00119	CcSEcCtD
Meloxicam—Decreased appetite—Dexamethasone—ankylosing spondylitis	8.05e-05	0.00119	CcSEcCtD
Meloxicam—Infection—Prednisone—ankylosing spondylitis	8.01e-05	0.00119	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	7.99e-05	0.00119	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	7.99e-05	0.00119	CcSEcCtD
Meloxicam—Back pain—Methotrexate—ankylosing spondylitis	7.98e-05	0.00119	CcSEcCtD
Meloxicam—Fatigue—Betamethasone—ankylosing spondylitis	7.98e-05	0.00119	CcSEcCtD
Meloxicam—Fatigue—Dexamethasone—ankylosing spondylitis	7.98e-05	0.00119	CcSEcCtD
Meloxicam—Shock—Prednisone—ankylosing spondylitis	7.93e-05	0.00118	CcSEcCtD
Meloxicam—Pain—Dexamethasone—ankylosing spondylitis	7.91e-05	0.00118	CcSEcCtD
Meloxicam—Pain—Betamethasone—ankylosing spondylitis	7.91e-05	0.00118	CcSEcCtD
Meloxicam—Nervous system disorder—Prednisone—ankylosing spondylitis	7.9e-05	0.00117	CcSEcCtD
Meloxicam—Tachycardia—Prednisone—ankylosing spondylitis	7.87e-05	0.00117	CcSEcCtD
Meloxicam—Skin disorder—Prednisone—ankylosing spondylitis	7.83e-05	0.00116	CcSEcCtD
Meloxicam—Hyperhidrosis—Prednisone—ankylosing spondylitis	7.79e-05	0.00116	CcSEcCtD
Meloxicam—Vision blurred—Methotrexate—ankylosing spondylitis	7.78e-05	0.00116	CcSEcCtD
Meloxicam—Ill-defined disorder—Methotrexate—ankylosing spondylitis	7.66e-05	0.00114	CcSEcCtD
Meloxicam—Anaemia—Methotrexate—ankylosing spondylitis	7.63e-05	0.00113	CcSEcCtD
Meloxicam—Feeling abnormal—Betamethasone—ankylosing spondylitis	7.63e-05	0.00113	CcSEcCtD
Meloxicam—Feeling abnormal—Dexamethasone—ankylosing spondylitis	7.63e-05	0.00113	CcSEcCtD
Meloxicam—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	7.57e-05	0.00112	CcSEcCtD
Meloxicam—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	7.57e-05	0.00112	CcSEcCtD
Meloxicam—Hypersensitivity—Triamcinolone—ankylosing spondylitis	7.52e-05	0.00112	CcSEcCtD
Meloxicam—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	7.5e-05	0.00111	CcSEcCtD
Meloxicam—Malaise—Methotrexate—ankylosing spondylitis	7.44e-05	0.00111	CcSEcCtD
Meloxicam—Vertigo—Methotrexate—ankylosing spondylitis	7.42e-05	0.0011	CcSEcCtD
Meloxicam—Leukopenia—Methotrexate—ankylosing spondylitis	7.39e-05	0.0011	CcSEcCtD
Meloxicam—Urticaria—Dexamethasone—ankylosing spondylitis	7.35e-05	0.00109	CcSEcCtD
Meloxicam—Urticaria—Betamethasone—ankylosing spondylitis	7.35e-05	0.00109	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	7.34e-05	0.00109	CcSEcCtD
Meloxicam—Dizziness—Prednisolone—ankylosing spondylitis	7.33e-05	0.00109	CcSEcCtD
Meloxicam—Asthenia—Triamcinolone—ankylosing spondylitis	7.32e-05	0.00109	CcSEcCtD
Meloxicam—Abdominal pain—Betamethasone—ankylosing spondylitis	7.32e-05	0.00109	CcSEcCtD
Meloxicam—Body temperature increased—Betamethasone—ankylosing spondylitis	7.32e-05	0.00109	CcSEcCtD
Meloxicam—Body temperature increased—Dexamethasone—ankylosing spondylitis	7.32e-05	0.00109	CcSEcCtD
Meloxicam—Abdominal pain—Dexamethasone—ankylosing spondylitis	7.32e-05	0.00109	CcSEcCtD
Meloxicam—Asthenia—Methylprednisolone—ankylosing spondylitis	7.3e-05	0.00108	CcSEcCtD
Meloxicam—Insomnia—Prednisone—ankylosing spondylitis	7.29e-05	0.00108	CcSEcCtD
Meloxicam—Paraesthesia—Prednisone—ankylosing spondylitis	7.24e-05	0.00107	CcSEcCtD
Meloxicam—Pruritus—Triamcinolone—ankylosing spondylitis	7.22e-05	0.00107	CcSEcCtD
Meloxicam—Cough—Methotrexate—ankylosing spondylitis	7.2e-05	0.00107	CcSEcCtD
Meloxicam—Pruritus—Methylprednisolone—ankylosing spondylitis	7.2e-05	0.00107	CcSEcCtD
Meloxicam—Convulsion—Methotrexate—ankylosing spondylitis	7.15e-05	0.00106	CcSEcCtD
Meloxicam—Dyspepsia—Prednisone—ankylosing spondylitis	7.09e-05	0.00105	CcSEcCtD
Meloxicam—Arthralgia—Methotrexate—ankylosing spondylitis	7.03e-05	0.00104	CcSEcCtD
Meloxicam—Myalgia—Methotrexate—ankylosing spondylitis	7.03e-05	0.00104	CcSEcCtD
Meloxicam—Decreased appetite—Prednisone—ankylosing spondylitis	7.01e-05	0.00104	CcSEcCtD
Meloxicam—Rash—Prednisolone—ankylosing spondylitis	6.99e-05	0.00104	CcSEcCtD
Meloxicam—Dermatitis—Prednisolone—ankylosing spondylitis	6.99e-05	0.00104	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	6.98e-05	0.00104	CcSEcCtD
Meloxicam—Diarrhoea—Methylprednisolone—ankylosing spondylitis	6.96e-05	0.00103	CcSEcCtD
Meloxicam—Fatigue—Prednisone—ankylosing spondylitis	6.95e-05	0.00103	CcSEcCtD
Meloxicam—Headache—Prednisolone—ankylosing spondylitis	6.95e-05	0.00103	CcSEcCtD
Meloxicam—Discomfort—Methotrexate—ankylosing spondylitis	6.94e-05	0.00103	CcSEcCtD
Meloxicam—Constipation—Prednisone—ankylosing spondylitis	6.89e-05	0.00102	CcSEcCtD
Meloxicam—Confusional state—Methotrexate—ankylosing spondylitis	6.79e-05	0.00101	CcSEcCtD
Meloxicam—Dizziness—Triamcinolone—ankylosing spondylitis	6.75e-05	0.001	CcSEcCtD
Meloxicam—Anaphylactic shock—Methotrexate—ankylosing spondylitis	6.74e-05	0.001	CcSEcCtD
Meloxicam—Dizziness—Methylprednisolone—ankylosing spondylitis	6.73e-05	0.001	CcSEcCtD
Meloxicam—Infection—Methotrexate—ankylosing spondylitis	6.69e-05	0.000994	CcSEcCtD
Meloxicam—Feeling abnormal—Prednisone—ankylosing spondylitis	6.64e-05	0.000986	CcSEcCtD
Meloxicam—Asthenia—Betamethasone—ankylosing spondylitis	6.64e-05	0.000986	CcSEcCtD
Meloxicam—Asthenia—Dexamethasone—ankylosing spondylitis	6.64e-05	0.000986	CcSEcCtD
Meloxicam—Nervous system disorder—Methotrexate—ankylosing spondylitis	6.61e-05	0.000981	CcSEcCtD
Meloxicam—Thrombocytopenia—Methotrexate—ankylosing spondylitis	6.6e-05	0.000979	CcSEcCtD
Meloxicam—Gastrointestinal pain—Prednisone—ankylosing spondylitis	6.59e-05	0.000979	CcSEcCtD
Meloxicam—Nausea—Prednisolone—ankylosing spondylitis	6.59e-05	0.000978	CcSEcCtD
Meloxicam—Pruritus—Dexamethasone—ankylosing spondylitis	6.55e-05	0.000972	CcSEcCtD
Meloxicam—Pruritus—Betamethasone—ankylosing spondylitis	6.55e-05	0.000972	CcSEcCtD
Meloxicam—Skin disorder—Methotrexate—ankylosing spondylitis	6.54e-05	0.000972	CcSEcCtD
Meloxicam—Hyperhidrosis—Methotrexate—ankylosing spondylitis	6.51e-05	0.000967	CcSEcCtD
Meloxicam—Vomiting—Triamcinolone—ankylosing spondylitis	6.49e-05	0.000963	CcSEcCtD
Meloxicam—Vomiting—Methylprednisolone—ankylosing spondylitis	6.47e-05	0.000961	CcSEcCtD
Meloxicam—Rash—Triamcinolone—ankylosing spondylitis	6.43e-05	0.000955	CcSEcCtD
Meloxicam—Dermatitis—Triamcinolone—ankylosing spondylitis	6.43e-05	0.000954	CcSEcCtD
Meloxicam—Rash—Methylprednisolone—ankylosing spondylitis	6.42e-05	0.000953	CcSEcCtD
Meloxicam—Dermatitis—Methylprednisolone—ankylosing spondylitis	6.41e-05	0.000952	CcSEcCtD
Meloxicam—Urticaria—Prednisone—ankylosing spondylitis	6.4e-05	0.000951	CcSEcCtD
Meloxicam—Headache—Triamcinolone—ankylosing spondylitis	6.39e-05	0.000949	CcSEcCtD
Meloxicam—Headache—Methylprednisolone—ankylosing spondylitis	6.38e-05	0.000947	CcSEcCtD
Meloxicam—Abdominal pain—Prednisone—ankylosing spondylitis	6.37e-05	0.000946	CcSEcCtD
Meloxicam—Body temperature increased—Prednisone—ankylosing spondylitis	6.37e-05	0.000946	CcSEcCtD
Meloxicam—Diarrhoea—Betamethasone—ankylosing spondylitis	6.33e-05	0.00094	CcSEcCtD
Meloxicam—Diarrhoea—Dexamethasone—ankylosing spondylitis	6.33e-05	0.00094	CcSEcCtD
Meloxicam—Hypotension—Methotrexate—ankylosing spondylitis	6.29e-05	0.000935	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	6.14e-05	0.000911	CcSEcCtD
Meloxicam—Dizziness—Dexamethasone—ankylosing spondylitis	6.12e-05	0.000909	CcSEcCtD
Meloxicam—Dizziness—Betamethasone—ankylosing spondylitis	6.12e-05	0.000909	CcSEcCtD
Meloxicam—Insomnia—Methotrexate—ankylosing spondylitis	6.09e-05	0.000905	CcSEcCtD
Meloxicam—Nausea—Triamcinolone—ankylosing spondylitis	6.06e-05	0.0009	CcSEcCtD
Meloxicam—Paraesthesia—Methotrexate—ankylosing spondylitis	6.05e-05	0.000898	CcSEcCtD
Meloxicam—Nausea—Methylprednisolone—ankylosing spondylitis	6.05e-05	0.000898	CcSEcCtD
Meloxicam—Dyspnoea—Methotrexate—ankylosing spondylitis	6.01e-05	0.000892	CcSEcCtD
Meloxicam—Somnolence—Methotrexate—ankylosing spondylitis	5.99e-05	0.000889	CcSEcCtD
Meloxicam—Hypersensitivity—Prednisone—ankylosing spondylitis	5.94e-05	0.000882	CcSEcCtD
Meloxicam—Dyspepsia—Methotrexate—ankylosing spondylitis	5.93e-05	0.000881	CcSEcCtD
Meloxicam—Vomiting—Dexamethasone—ankylosing spondylitis	5.88e-05	0.000874	CcSEcCtD
Meloxicam—Vomiting—Betamethasone—ankylosing spondylitis	5.88e-05	0.000874	CcSEcCtD
Meloxicam—Decreased appetite—Methotrexate—ankylosing spondylitis	5.86e-05	0.00087	CcSEcCtD
Meloxicam—Rash—Dexamethasone—ankylosing spondylitis	5.84e-05	0.000867	CcSEcCtD
Meloxicam—Rash—Betamethasone—ankylosing spondylitis	5.84e-05	0.000867	CcSEcCtD
Meloxicam—Dermatitis—Betamethasone—ankylosing spondylitis	5.83e-05	0.000866	CcSEcCtD
Meloxicam—Dermatitis—Dexamethasone—ankylosing spondylitis	5.83e-05	0.000866	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	5.82e-05	0.000864	CcSEcCtD
Meloxicam—Fatigue—Methotrexate—ankylosing spondylitis	5.81e-05	0.000862	CcSEcCtD
Meloxicam—Headache—Betamethasone—ankylosing spondylitis	5.8e-05	0.000861	CcSEcCtD
Meloxicam—Headache—Dexamethasone—ankylosing spondylitis	5.8e-05	0.000861	CcSEcCtD
Meloxicam—Asthenia—Prednisone—ankylosing spondylitis	5.78e-05	0.000859	CcSEcCtD
Meloxicam—Pain—Methotrexate—ankylosing spondylitis	5.76e-05	0.000855	CcSEcCtD
Meloxicam—Pruritus—Prednisone—ankylosing spondylitis	5.7e-05	0.000847	CcSEcCtD
Meloxicam—Feeling abnormal—Methotrexate—ankylosing spondylitis	5.55e-05	0.000824	CcSEcCtD
Meloxicam—Diarrhoea—Prednisone—ankylosing spondylitis	5.51e-05	0.000819	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	5.51e-05	0.000818	CcSEcCtD
Meloxicam—Nausea—Dexamethasone—ankylosing spondylitis	5.5e-05	0.000816	CcSEcCtD
Meloxicam—Nausea—Betamethasone—ankylosing spondylitis	5.5e-05	0.000816	CcSEcCtD
Meloxicam—Urticaria—Methotrexate—ankylosing spondylitis	5.35e-05	0.000795	CcSEcCtD
Meloxicam—Dizziness—Prednisone—ankylosing spondylitis	5.33e-05	0.000792	CcSEcCtD
Meloxicam—Body temperature increased—Methotrexate—ankylosing spondylitis	5.32e-05	0.000791	CcSEcCtD
Meloxicam—Abdominal pain—Methotrexate—ankylosing spondylitis	5.32e-05	0.000791	CcSEcCtD
Meloxicam—Vomiting—Prednisone—ankylosing spondylitis	5.12e-05	0.000761	CcSEcCtD
Meloxicam—Rash—Prednisone—ankylosing spondylitis	5.08e-05	0.000755	CcSEcCtD
Meloxicam—Dermatitis—Prednisone—ankylosing spondylitis	5.08e-05	0.000754	CcSEcCtD
Meloxicam—Headache—Prednisone—ankylosing spondylitis	5.05e-05	0.00075	CcSEcCtD
Meloxicam—Hypersensitivity—Methotrexate—ankylosing spondylitis	4.96e-05	0.000737	CcSEcCtD
Meloxicam—Asthenia—Methotrexate—ankylosing spondylitis	4.83e-05	0.000718	CcSEcCtD
Meloxicam—Nausea—Prednisone—ankylosing spondylitis	4.79e-05	0.000711	CcSEcCtD
Meloxicam—Pruritus—Methotrexate—ankylosing spondylitis	4.77e-05	0.000708	CcSEcCtD
Meloxicam—Diarrhoea—Methotrexate—ankylosing spondylitis	4.61e-05	0.000684	CcSEcCtD
Meloxicam—Dizziness—Methotrexate—ankylosing spondylitis	4.45e-05	0.000662	CcSEcCtD
Meloxicam—Vomiting—Methotrexate—ankylosing spondylitis	4.28e-05	0.000636	CcSEcCtD
Meloxicam—Rash—Methotrexate—ankylosing spondylitis	4.25e-05	0.000631	CcSEcCtD
Meloxicam—Dermatitis—Methotrexate—ankylosing spondylitis	4.24e-05	0.00063	CcSEcCtD
Meloxicam—Headache—Methotrexate—ankylosing spondylitis	4.22e-05	0.000627	CcSEcCtD
Meloxicam—Nausea—Methotrexate—ankylosing spondylitis	4e-05	0.000594	CcSEcCtD
